- The term "biogeneric"
can simply be defined as a pharmaceutical preparation based on a
biologically active substance. This is in contrast to traditional,
multisource, generic pharmaceuticals.
- A biogeneric is defined
as the generic alternative of a biopharmaceutical or biologic, which is
a copy of the original product.
- The total
biopharmaceutical market is valued at US $ 18,000 million with the US
accounting for the largest proportion, 45%, followed by Europe, 30%,
Japan, 20%, and the rest of the world, 5%. Assuming a similar
penetration rate for biogenerics as for traditional drugs , then the
potential market for biogenerics would be estimated at US$ 2,000
million.
- Globally, the generic
pharmaceutical business generated approximately $33 billion in revenue
in 2002 . The financial success of the generic pharmaceutical industry
has led many industry thought leaders and company executives to consider
developing and manufacturing generic versions of blockbuster
biopharmaceuticals near patent expiry such as Epogen
(erythropoietin-alpha, EPO),Neupogen, (granulocyte colony stimulating
factor, G-CSF), and Avonex (interferon-beta).
- At present, India is
one of the major contributors in the world biogeneric market along with
China. The entry of Indian firms, with their own brands of recombinant
products, has changed the dynamics of the domestic biogenerics
market.
- With low capital and
operational cost in the area of bio-manufacturing, industry estimates
that the market for biogenerics in India is expected to see a 43 percent
jump from Rs 308.50 crore in 2001 to Rs 1,305.7 crore in 2005 and
projected to reach Rs 1,864.3 crore by 2007 registering a growth of 19
percent.
- The main players in
Biogenerics market are Sandoz, Cangene, LG Chemicals, Rhein Biotech,
PCGen, Wockhardt, Microbix, GeneMedix, Stada, DSM Biologicals, and
Amgen.
|
General Information
- What Next for
Biogenerics?
- Biotech Feature
- The Future of
Biogenerics
- Potential Savings Of
Biogenerics In the United States
Production and
Processing
- Biogeneric race in Europe
- A Lisbon Strategy for
Pharmaceuticals
- Competitor Analysis
Biogenerics and Therepautic-Protein
-
Technology
- Bioscience
Technology
- Biogenerics Subsidiary Tyche
Energy Acquires Rights to Hydroslotter Technology
- Generic Biotech
- Key Challenges Facing
Biomanufacturing
Company
Profile
- BioProcess Group
- Bicon
- Cangene
Corporation
- Reliance Life Sciences Group of Companies
- InSight Biopharmaceuticals Ltd
- Microbix
- Procognia (Israel)
Ltd
- Rhein Biotech
- Sandoz
- STADA
Consultants
- Avalon
Consulting
- Bioventure
Consultants
- C.E.L for Pharma
- Lash Group
|
Market
- Business Case
- Citizens Against
Government Waste
- The Next Boom in the
Biotech World
- India as a hub for
biogenerics
- Diagnostics in Gene and
Protein Expression
- Biogenerics market set to explode?
- Biogenerics market gaining momentum
- A Strategic Market
Outlook and Business Analysis
- Biogenerics A Priority
Review
- The Science Business
Roundtable
Innovation
- Biogenerics
Policies
- Biogenerics: An Answer
to High Prices or Highly Risk Business
- Australia and New
Zealand Health
Policy
- Prescription Drug User
Fee Act
- Chronical
Specials
- Time for an
approval pathway from Congress
- The Need for a Generic
Pathway
Reports
- Challenges and
Promise
- A New Level of
Complexity
- Western Biotech not
threatened by Generic East – according to a new
survey by Eden
Biodesign
- Pharmacy Times
- Biotechnology In
India
- Woodchips, Stalks and
Switch Grass makes Biogenerics Easy
Order the CD ROM
Today |